Citation Report
List of articles citing

Sildenafil for pulmonary hypertension

DOI: 10.1345/aph.1e426
Annals of Pharmacotherapy, 2005, 39, 869-84.

#	Paper	IF	Citations
37	Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. *British Journal of Haematology*, **2005**, 130, 445-53	4.5	170
36	New therapeutic strategies for systemic sclerosis--a critical analysis of the literature. *Clinical and Developmental Immunology*, **2005**, 12, 165-73		37
35	Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. *Journal of Cardiothoracic and Vascular Anesthesia*, **2006**, 20, 722-35	2.1	22
34	Retrospective Evaluation of Sildenafil Citrate as a Therapy for Pulmonary Hypertension in Dogs. *Journal of Veterinary Internal Medicine*, **2006**, 20, 1132-1135	3.1	77
33	Are phosphodiesterase 4 inhibitors just more theophylline?. *Journal of Allergy and Clinical Immunology*, **2006**, 117, 1237-43	11.5	91
32	Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin gene-related peptide. *Life Sciences*, **2006**, 78, 1830-8	6.8	17
31	Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodelling. *International Journal of Experimental Pathology*, **2006**, 87, 463-74	2.8	66
30	Effect of sildenafil on pulmonary haemodynamics in patients with valvular heart disease. *European Journal of Anaesthesiology*, **2006**, 23, 34	2.3	
29	Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. *Journal of Experimental Medicine*, **2006**, 203, 2691-702	16.6	588
28	Sildenafil for pulmonary arterial hypertension: when blue turns into white. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 1801-10	4	4
27	The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. *Current Topics in Medicinal Chemistry*, **2007**, 7, 437-54	3	57
26	Molecule of the Month. *Current Topics in Medicinal Chemistry*, **2007**, 7, 637-637	3	
25	Pharmacotherapy of High-Altitude Illness. *American Journal of Lifestyle Medicine*, **2007**, 1, 129-141	1.9	1
24	Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources. *Cardiology in the Young*, **2007**, 17, 72-7	1	11
23	Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate. *Internal Medicine*, **2007**, 46, 893-8	1.1	3
22	Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. *Journal of Cardiothoracic and Vascular Anesthesia*, **2007**, 21, 203-7	2.1	34
21	Translational research in the pharmaceutical industry: from theory to reality. *Drug Discovery Today*, **2007**, 12, 419-25	8.8	17

20	Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. *European Journal of Pharmacology*, **2007**, 572, 12-22	5.3	93
19	Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. *Pulmonary Pharmacology and Therapeutics*, **2008**, 21, 516-21	3.5	7
18	Role of combination therapy in the treatment of pulmonary arterial hypertension. *Pharmacotherapy*, **2010**, 30, 390-404	5.8	7
17	Clinical use of sildenafil in pulmonary artery hypertension. *Expert Review of Respiratory Medicine*, **2010**, 4, 13-9	3.8	11
16	Regulation of cAMP by phosphodiesterases in erythrocytes. *Pharmacological Reports*, **2010**, 62, 475-82	3.9	30
15	Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the lung for pulmonary hypertension. *Methods in Molecular Biology*, **2010**, 610, 309-21	1.4	7
14	Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases. *Current Topics in Medicinal Chemistry*, **2012**, 12, 1224-36	3	15
13	Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer\'s disease. *European Journal of Medicinal Chemistry*, **2013**, 60, 285-94	6.8	73
12	Scleroderma therapy: clinical overview of current trends and future perspective. *Rheumatology International*, **2013**, 33, 1-18	3.6	12
11	CONTEMPORARY APPROACH TO THE CORRECTION OF COGNITIVE DISORDERS IN PATIENTS WITH VASCULAR COMORBIDITY. *Rational Pharmacotherapy in Cardiology*, **2013**, 9, 158-162	0.5	0
10	Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor. *International Journal of Pharmaceutics*, **2017**, 517, 312-321	6.5	44
9	cGMP modulation therapeutics for sickle cell disease. *Experimental Biology and Medicine*, **2019**, 244, 132-146	3.7	14
8	Role of Medicinal Plants in Pulmonary Hypertension. **2021**, 303-316		0
7	The vascular system. **2012**, 265-284		1
6	Pulmonary Hypertension Secondary to Bronchopulmonary Dysplasia in Very Low Birth Weight Infants (. *Journal of the Korean Society of Neonatology*, **2011**, 18, 96		3
5	The vascular system. **2007**, 298-320		1
4	Diuretics. **2014**, 143-155		
3	The first Russian experience of sildenafil application in patients with idiopathic pulmonary hypertension. *Systemic Hypertension*, **2015**, 12, 50-55	1.6	

2	APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION. **2015**, 42-49	2
1	Soluble guanylate cyclase stimulator riociguat in the palette of modern specific therapy for precapillary pulmonary hypertension: from the pathophysiological basis to the results of current research. **2023**, 19, 45-52	0